ALSO NOTED: Avastin delivers promising data for brain cancer; Genelabs regains development rights; and much more...

> A mid-stage study of Avastin shows promising results in treating a form of brain cancer. Release

> Genelabs Technologies says it's regained development rights to the experimental lupus drug Prestara from Mitsubishi Tanabe Pharma. Release

> Keryx Biopharma has presented early results from a mid-stage study of perifosine or KRX-0401 in patients with recurrent malignant gliomas. Release

> Here's some somber news: The FDA has tallied more than 200 reports of deaths linked to Trasylol, the suspended blood-clotting drug made by Bayer. Report

> Pfizer whistleblower Dr. Peter Rost (photo) will get his day in court. The U.S. Court of Appeals has overruled an earlier ruling, reinstating Rost's suit against the company. Report

> Poor Puerto Rico. Pharmaceuticals firms are shutting down plants in the U.S. territory, eliminating some 3,000 jobs. Report

> It looks like a drug, it acts like a drug, but if comes in a cosmetics tube instead of an eyedropper, is it still a drug? Lumigan, a glaucoma remedy sold by Allergan, has the unusual added benefit of promoting eyelash growth. Report

And Finally… The melatonin supplements that many people take to fight jet lag could have a down side inhibiting memory formation. Release

Suggested Articles

I-MAB's anti-GM-CSF drug works "upstream" in inflammation pathways, potentially blocking several dangerous cytokines in COVID-19, executives…

Antibe's lead drug beat placebo at reducing osteoarthritis pain, boosting its case as an alternative to NSAIDs, commonly used to treat the condition.

The trial marks the start of a new phase of the response to SARS-CoV-2 in which people will receive drugs designed specifically for the virus.